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Creatine kinase (CK; EC 2.7.3.2) is related to several skin diseases such as psoriasis and dermatomyositis. CK is important in
skin energy homeostasis because it catalyzes the reversible transfer of a phosphoryl group from MgATP to creatine. In this study,
we predicted CK binding proteins via the use of bioinformatic tools such as protein-protein interaction (PPI) mappings and
suggest the putative hub proteins for CK interactions. We obtained 123 proteins for brain type CK and 85 proteins for muscle
type CK in the interaction networks. Among them, several hub proteins such as NFKB1, FHL2, MYOC, and ASB9 were predicted.
Determination of the binding factors of CK can further promote our understanding of the roles of CK in physiological conditions.
1.Introduction
Creatinekinase(CK)(ATP:creatinekinaseN-phosphotrans-
ferase, EC 2.7.3.2) is thought to be crucial for intracellular
transport and the storage of high energy phosphate because
itcatalyzesthereversibletransferofaphosphorylgroupfrom
MgATP to creatine, which leads to the creation of phospho-
creatine and MgADP [1]. CK plays an important role in the
cellular energy metabolism of vertebrates, and it is widely
distributed in tissues that require a lot of energy [2]. Several
types of CK are expressed in various tissues: the muscle
and brain types of CK are the most common, and three
diﬀerent isoenzymes that include CK-MM (the muscle type
homodimer), CK-BB (the brain type homodimer), and CK-
MB (the muscle plus brain type heterodimer) originate from
these two common types. CK is an important serum marker
for myocardial infarction. Various types of CKs (the muscle,
brain, and mitochondrial types) are thought to be important
not only in the diagnosis of myocardial infarction, cardiac
hypertrophy, and muscular dystrophy but also for studies of
some other serious diseases, including Alzheimer’s disease,
Parkinson’s disease, and psoriasis [3–8].
CK-BB is associated with several pathologies, includ-
ing neurodegenerative and age-related diseases. Recently,
Chang et al. [9]r e p o r t e da ni m p o r t a n tr o l ef o rC K - B Bi n
osteoclast-mediated bone resorption, which was found using
a proteomics approach. They found that CK-BB is greatly
increased during osteoclastogenesis and suggested that it
represents a potential target for antiresorptive drug develop-
ment. CK-BB interacts with the potassium-chloride cotrans-
porter 3, which is involved in the pathophysiology of hered-
itary motor and sensory neuropathy with agenesis of the
corpuscallosum[10].Previousstudies[11,12]havereported
that CK-BB is involved in Alzheimer’s disease (AD) as an
oxidatively modiﬁed protein. This suggests that oxidatively
damaged CK-BB may be associated with aging and age-
related neurodegenerative disorders such as AD.
CK-MM is a good model to use for studying folding
pathways because of several characteristics: (i) it is a dimer2 Enzyme Research
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Figure 1: PPI map for CKB as a target hub protein with the 80% identity. Labels with red color indicate the hub protein of targeting. The
image was made by the aiSee program (http://www.aisee.com/).
thatconsistsoftwoidentical subunits,eachwithanN-termi-
nal domain with about 100 residues and a C-terminal do-
main with about 250 residues connected by a long linker
[13]; (ii) extensively denatured CK can be renatured spon-
taneously with restoration of its enzymatic activity in the
absence of any external assistance [14]; (iii) its folding path-
way is complicated and involves several intermediates [15,
16]; (iv) conformational changes of the secondary and terti-
ary structures can be easily measured by monitoring activity
changes [14, 15]; (v) protein-protein interactions, including
molecular chaperones, are observed during refolding [17,
18].
In this study, we obtained computational predictions of
the binding proteins by using two types of CK (CK-BB and
CK-MM) as hub proteins in bioinformatic algorithms. As a
result, we obtained 208 protein lists in the interaction net-
works via application of both muscle and brain types of CK.
Determination of the binding factors and functions of CK
can further promote our understanding of the physiological
roles of CK.
2.MaterialsandMethods
2.1. PPI Mappings: PEIMAP and PSIMAP Algorithms. We
present the functionally classiﬁed protein-protein interac-
tions on the basis of the cell cycle, cell transport, oxidore-
ductase, and apoptosis. PPI resources were assembled from
a combination of several experimental protein interaction
databases. The protein interaction resources included six
databases: DIP [19], BIND [20], IntAct [21], MINT [22],
HPRD [23], and BioGrid [24]. We performed a redundancy
test to remove identical protein sequences from the interac-
tion databases. The databases contain 116,773 proteins and
229,799 interactions.
PPI prediction uses most of the major types of PPI algo-
rithms. They are (1) Protein Structural Interactome MAP
(PSIMAP), a method that uses the structural domain of the
SCOP (Structural Classiﬁcation of Proteins) database [25]
and (2) Protein Experimental Interactome MAP (PEIMAP),
a common method that uses public resources of experimen-
tal protein interaction information such as HPRD, BIND,
DIP, MINT, IntAct; and BioGrid. The basic procedure of
PSIMAP is to infer interactions between proteins by using
their homologs. Interactions among domains or proteins for
known PDB (Protein Data Bank) structures are the basis
for the prediction. If an unknown protein has a homolog to
adomain,thenPSIMAPassumesthatthequeryhastheprob-
ability to interact with its homolog’s partners. This concept
is called “homologous interaction.” The original interaction
between two proteins or domains is based on the Euclidean
distance. Therefore, PSIMAP gives a structure-based inter-
action prediction [26]. PEIMAP was constructed by com-
bining several experimental protein-protein interaction da-
tabases. We carried out a redundancy check to remove
identical protein sequences from the source interactionEnzyme Research 3
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Figure 2: PPI map for CKB as a target hub protein with the 100% identity. The methodological conditions were the same as for Figure 1
except the identity.
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Figure 3: PPI map for CKM as a target hub protein with the 80% identity. Labels with red color indicate the hub protein of targeting. The
image was made by the aiSee program (http://www.aisee.com/).4 Enzyme Research
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Figure 4: PPI map for CKM as a target hub protein with the 100% identity. The methodological conditions were the same as for Figure 3
except the identity.
databases. The image was made by the Pajak2.00 program
(http://vlado.fmf.uni-lj.si/pub/networks/pajek/).
3. Results andDiscussion
We identiﬁed potential candidates through protein-protein
interaction predictions made using various protein interac-
tion resources. By analyzing the hub protein of the networks
with metrics such as degree and centrality, we detected 123
potential candidates for CKB interacting (direct or indirect)
factors and 85 candidates for CKM.
In Figure 1, interacting factors such as NFKB1
(NP 003989, nuclear factor of kappa light polypeptide gene
enhancer in B-cells 1), MYOC (NP 000252; myocilin,
trabecular meshwork inducible glucocorticoid response),
MYOM2 (NP 003961; myomesin (M-protein) 2, 165kDa),
FHL2 (NP 001034581, four-and-a-half LIM domains 2),
HIF1AN(NP 060372, hypoxia-inducible factor1,alphasub-
unit inhibitor), ASB9 (NP 076992, ankyrin repeat and SOCS
box-containing 9), and CKM (NP 001815, creatine kinase,
muscle) were elucidated. Interestingly, NFKB1 was detected
as a hub protein interacting with CK-BB in our results. In
Figure 2, we obtained results similar to those from Figure 1,
where NFKB1, MYOC, MYOM2, FHL2, HIF1AN, ASB9, and
CKM were detected as interacting factors that were directly
or indirectly associated with CKB. NFKB1, CKM, and ASB9
interacted with CKB directly.
In the same way, we detected the CKM-associated
proteins as shown in Figure 3 with 80% sequence iden-
tity. As a result, we found that CKB, FHL2, MYOC,
ASB9, HIF1AN, NFKB1, TTN (NP 596870, titin), MYH9
(NP 002464,myosin,heavychain9,non-muscle),andITGA7
(NP 002197, integrin, alpha 7) mainly interacted with CKM
at 80% sequence identity. At the level of 100% identity,
we found that MYOM2, CKB, FHL2, and MYOC directly
interacted with CKM as shown in Figure 4. In addition to
these factors, complete lists of factors that interacted with
CKB and CKM in a direct or indirect manner are shown in
Tables 1 and 2. After overlapping the results from Figures
1 to 4, we found that NFKB1, FHL2, and MYOC were still
detected as hub proteins in Figure 5.
NFKB1 (also known as p50 or NF-kappaB) is a well-
known transcription regulator that is responsible for the
expression and regulation of many genes for immune re-
sponse, cell adhesion, diﬀerentiation, proliferation, angiog-
enesis, and apoptosis [27–31]. It translocates into the nu-
cleus and stimulates the expression of many genes involved
invariousbiologicalfunctions.NFKB1isalsoassociatedwith
a number of inﬂammatory diseases such as lymphoma [32],
Alzheimer disease [33], psoriatic arthritis [34], breast cancer
[35, 36], and rheumatoid arthritis [37]. Activation of
NFKB1 requires binding of NF-kappaB essential modulator
(NEMO) to ubiquitinated substrates [38]. With respect to
an association with CK, it has been reported that NFKB1
is mostly associated with myocardial ischemia/reperfusion.Enzyme Research 5
Table 1: Gene lists for the analyses of the PEIMAP and PSIMAP using CK-BB as a hub protein with 100% identity.
Gene ID Gene symbol Full name
6256 RXRA Retinoid X receptor, alpha
3309 HSPA5 Heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa)
3320 HSP90AA1 Heat shock protein 90kDa alpha (cytosolic), class A member 1
2908 NR3C1 Nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)
6778 STAT6 Signal transducer and activator of transcription 6, interleukin-4 induced
3146 HMGB1 High-mobility group box 1
3301 DNAJA1 DnaJ (Hsp40) homolog, subfamily A, member 1
4221 MEN1 Multiple endocrine neoplasia I
3312 HSPA8 Heat shock 70kDa protein 8
3840 KPNA4 Karyopherin alpha 4 (importin alpha 3)
2274 FHL2 Four-and-a-half LIM domains 2
4792 NFKBIA Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha
57805 KIAA1967 KIAA1967
3185 HNRNPF Heterogeneous nuclear ribonucleoprotein F
203068 TUBB Tubulin, beta
6774 STAT3 Signal transducer and activator of transcription 3 (acute-phase response factor)
4670 HNRNPM Heterogeneous nuclear ribonucleoprotein M
1997 ELF1 E74-like factor 1 (ets domain transcription factor)
113457 TUBA3D Tubulin, alpha 3D
1999 ELF3 E74-like factor 3 (ets domain transcription factor, epithelial-speciﬁc)
5591 PRKDC Protein kinase, DNA-activated, catalytic polypeptide
708 C1QBP Complement component 1, q subcomponent binding protein
2274 FHL2 Four-and-a-half LIM domains 2
3313 HSPA9 Heat shock 70kDa protein 9 (mortalin)
8600 TNFSF11 Tumor necrosis factor (ligand) superfamily, member 11
3659 IRF1 Interferon regulatory factor 1
84617 TUBB6 Tubulin, beta 6
7280 TUBB2A Tubulin, beta 2A
2908 NR3C1 Nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)
2908 NR3C1 Nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)
8517 IKBKG Inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase gamma
7295 TXN Thioredoxin
10318 TNIP1 TNFAIP3 interacting protein 1
4793 NFKBIB Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, beta
3065 HDAC1 Histone deacetylase 1
3551 IKBKB inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta
1152 CKB Creatine kinase, brain
4069 LYZ Lysozyme (renal amyloidosis)
140462 ASB9 Ankyrin repeat and SOCS box-containing 9
4653 MYOC Myocilin, trabecular meshwork inducible glucocorticoid response
6774 STAT3 Signal transducer and activator of transcription 3 (acute-phase response factor)
3660 IRF2 Interferon regulatory factor 2
7278 TUBA3C Tubulin, alpha 3c
4221 MEN1 Multiple endocrine neoplasia I
5966 REL v-rel reticuloendotheliosis viral oncogene homolog (avian)
1147 CHUK Conserved helix-loop-helix ubiquitous kinase
55922 NKRF NFKB repressing factor
2113 ETS1 v-ets erythroblastosis virus E26 oncogene homolog 1 (avian)
64332 NFKBIZ Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, zeta6 Enzyme Research
Table 1: Continued.
Gene ID Gene symbol Full name
51773 RSF1 Remodeling and spacing factor 1
5971 RELB v-rel reticuloendotheliosis viral oncogene homolog B
1832 DSP Desmoplakin
347733 TUBB2B Tubulin, beta 2B
2353 FOS v-fos FBJ murine osteosarcoma viral oncogene homolog
9325 TRIP4 Thyroid hormone receptor interactor 4
4435 CITED1 Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 1
22984 PDCD11 Programmed cell death 11
790 CAD Carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase
1326 MAP3K8 Mitogen-activated protein kinase kinase kinase 8
1917 EEF1A2 Eukaryotic translation elongation factor 1 alpha 2
9172 MYOM2 Myomesin (M-protein) 2, 165kDa
10856 RUVBL2 RuvB-like 2 (E. coli)
1158 CKM Creatine kinase, muscle
808 CALM3 Calmodulin 3 (phosphorylase kinase, delta)
672 BRCA1 Breast cancer 1, early onset
801 CALM1 Calmodulin 1 (phosphorylase kinase, delta)
293 SLC25A6 Solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 6
3310 HSPA6 Heat shock 70kDa protein 6 (HSP70B )
2908 NR3C1 Nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)
136319 MTPN Myotrophin
2274 FHL2 Four-and-a-half LIM domains 2
9093 DNAJA3 DnaJ (Hsp40) homolog, subfamily A, member 3
4628 MYH10 Myosin, heavy chain 10, non-muscle
4221 MEN1 Multiple endocrine neoplasia I
6774 STAT3 Signal transducer and activator of transcription 3 (acute-phase response factor)
3839 KPNA3 Karyopherin alpha 3 (importin alpha 4)
57805 KIAA1967 KIAA1967
2908 NR3C1 Nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)
1869 E2F1 E2F transcription factor 1
55662 HIF1AN Hypoxia-inducible factor 1, alpha subunit inhibitor
79155 TNIP2 TNFAIP3 interacting protein 2
9532 BAG2 BCL2-associated athanogene 2
6421 SFPQ Splicing factor proline/glutamine-rich (polypyrimidine tract binding protein associated)
2908 NR3C1 Nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)
10627 MRCL3 Myosin regulatory light chain MRCL3
7431 VIM Vimentin
672 BRCA1 Breast cancer 1, early onset
2274 FHL2 Four-and-a-half LIM domains 2
4221 MEN1 Multiple endocrine neoplasia I
672 BRCA1 Breast cancer 1, early onset
4221 MEN1 Multiple endocrine neoplasia I
3836 KPNA1 Karyopherin alpha 1 (importin alpha 5)
3093 UBE2K Ubiquitin-conjugating enzyme E2K (UBC1 homolog, yeast)
805 CALM2 Calmodulin 2 (phosphorylase kinase, delta)
5970 RELA v-rel reticuloendotheliosis viral oncogene homolog A (avian)
9782 MATR3 Matrin 3
8600 TNFSF11 Tumor necrosis factor (ligand) superfamily, member 11
8607 RUVBL1 RuvB-like 1 (E. coli)Enzyme Research 7
Table 1: Continued.
Gene ID Gene symbol Full name
4627 MYH9 Myosin, heavy chain 9, nonmuscle
23421 ITGB3BP Integrin beta 3 binding protein (beta3-endonexin)
140462 ASB9 Ankyrin repeat and SOCS box-containing 9
4841 NONO Non-POU domain containing, octamer-binding
9276 COPB2 Coatomer protein complex, subunit beta 2 (beta prime)
4221 MEN1 Multiple endocrine neoplasia I
1213 CLTC Clathrin, heavy chain (Hc)
292 SLC25A5 Solute carrier family 25 (Mitochondrial carrier; adenine nucleotide translocator), member 5
4066 LYL1 Lymphoblastic leukemia-derived sequence 1
64332 NFKBIZ Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, zeta
5531 PPP4C Protein phosphatase 4 (formerly X), catalytic subunit
8091 HMGA2 High-mobility group AT-hook 2
6202 RPS8 Ribosomal protein S8
1051 CEBPB CCAAT/enhancer binding protein (C/EBP), beta
222643 UNC5CL Unc-5 homolog C (C. elegans)-like
4790 NFKB1 Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1
71 ACTG1 Actin, gamma 1
3312 HSPA8 Heat shock 70kDa protein 8
9782 MATR3 Matrin 3
3320 HSP90AA1 Heat shock protein 90kDa alpha (cytosolic), class A member 1
4637 MYL6 Myosin, light chain 6, alkali, smooth muscle and nonmuscle
2908 NR3C1 Nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)
4793 NFKBIB Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, beta
688 KLF5 Kruppel-like factor 5 (intestinal)
672 BRCA1 Breast cancer 1, early onset
During reperfusion, the absence of poly(ADP-ribose) pol-
ymerase-1 (PARP-1) leads to a reduction of myocardial apop-
tosis, which is associated with reduced NFKB1 activation
[39, 40], and proteasome inhibition ablates activation of
NFKB1 in myocardial reperfusion and reduces reperfusion
injury [41]. Myocardial injury was assessed by measuring the
s e ru ml ev e l so fC K ,a n dC Kw a sr e d u c e di ns e ru ma l o n gwi t h
reduction of NFKB1 activation.
FHL2 is a member of the human four-and-a-half-LIM-
only protein family, which consists of the members FHL1,
FHL2, FHL3, FHL4, and ACT. These proteins function in
various cellular processes, including regulation of cell sur-
vival, transcription, and signal transduction [42]. FHL2
contains an LIM domain, one of the protein-protein interac-
tion motifs, which allows speciﬁc proteins to combine with
certain partners. The speciﬁcity of a protein-protein inter-
action can be obtained by an interaction code predicted by
conserved amino acid sequences. The interaction of FHL2
withtranscriptionfactorsandotherproteinsinvolvedincan-
cer development was examined. Since transcription factors
control all fundamental developmental and homeostatic
processes, transcriptional cofactors such as FHL2 are likely
to contribute to human carcinogenesis and are of clinical
importance in various forms of cancer [43], including leu-
kemia [44]. With respect to an association with CK, Chung
et al. [45] reported that FHL2 (developmentally enhanced
phosphotransfer enzyme-anchoring protein) amalgamated
the myoﬁbrillar CK metabolic signaling circuit, providing
an energetic continuum between mitochondria and the
nascent contractile machinery in a murine embryonic stem
cell cardiac diﬀerentiation model. They reported that CK-
M clustered around developing myoﬁbrils, sarcolemma, and
the perinuclear compartment, whereas CK-B was tightly
associated with myoﬁbrillar alpha-actinin, forming wire-
like structures extending from the nuclear compartment to
the sarcolemma. FHL2 was also increased in myocardial
ischemia-reperfusion injury, where IL-6 and IL-8 mRNA are
upregulated in human cardiac myocytes [46].
Recently, ASB9 was found to interact with ubiquitous
mitochondrial CK [47]. The ankyrin repeat domains of
ASB9 can associate with the substrate binding site of CK
in a SOCS box-independent manner. The overexpression
of ASB9 induces ubiquitination of CK. ASB9 reduces CK
activitiesandcellgrowthandnegativelyregulatescellgrowth.
ASB9 is a member of the ankyrin repeat and is a suppressor
of the cytokine signaling (SOCS) box protein family. It can
interact with the SOCS box domain of the elongin B-C
adapter complex and can further complex with the cullin
and ring box proteins to form E3 ubiquitin ligase complexes
[48]. These complexes may be involved in speciﬁc substrate-
recognition for ubiquitination and degradation and mediate
the substrate-recognition of the E3 ubiquitin ligases.8 Enzyme Research
Table 2: Gene lists for the analyses of the PEIMAP and PSIMAP using CK-MM as a hub protein with 100% identity.
Gene ID Gene symbol Full name
1889 ECE1 Endothelin-converting enzyme 1
5981 RFC1 Replication factor C (activator 1) 1, 145kDa
226 ALDOA Aldolase A, fructose-bisphosphate
2335 FN1 Fibronectin 1
9372 ZFYVE9 Zinc ﬁnger, FYVE domain containing 9
60 ACTB Actin, beta
3688 ITGB1 Integrin, beta 1 (ﬁbronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12)
7273 TTN Titin
2274 FHL2 Four-and-a-half LIM domains 2
4853 NOTCH2 Notch homolog 2 (Drosophila)
2512 FTL Ferritin, light polypeptide
1192 CLIC1 Chloride intracellular channel 1
2274 FHL2 Four-and-a-half LIM domains 2
5313 PKLR Pyruvate kinase, liver and RBC
302 ANXA2 Annexin A2
7704 ZBTB16 Zinc ﬁnger and BTB domain containing 16
2200 FBN1 Fibrillin 1
27332 ZNF638 Zinc ﬁnger protein 638
92086 GGTLC1 Gamma-glutamyltransferase light chain 1
713 C1QB Complement component 1, q subcomponent, B chain
3029 HAGH Hydroxyacylglutathione hydrolase
5664 PSEN2 Presenilin 2 (Alzheimer disease 4)
7086 TKT Transketolase (Wernicke-Korsakoﬀ syndrome)
4176 MCM7 Minichromosome maintenance complex component 7
1152 CKB Creatine kinase, brain
1499 CTNNB1 Catenin (cadherin-associated protein), beta 1, 88kDa
140462 ASB9 Ankyrin repeat and SOCS box-containing 9
9457 FHL5 Four-and-a-half LIM domains 5
4653 MYOC Myocilin, trabecular meshwork inducible glucocorticoid response
3029 HAGH Hydroxyacylglutathione hydrolase
7704 ZBTB16 Zinc ﬁnger and BTB domain containing 16
3675 ITGA3 Integrin, alpha 3 (antigen CD49C, alpha 3 subunit of VLA-3 receptor)
226 ALDOA Aldolase A, fructose-bisphosphate
3689 ITGB2 Integrin, beta 2 (complement component 3 receptor 3 and 4 subunit)
3688 ITGB1 Integrin, beta 1 (ﬁbronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12)
302 ANXA2 Annexin A2
92086 GGTLC1 Gamma-glutamyltransferase light chain 1
3679 ITGA7 Integrin, alpha 7
2023 ENO1 Enolase 1, (alpha)
9172 MYOM2 Myomesin (M-protein) 2, 165kDa
1158 CKM Creatine kinase, muscle
4790 NFKB1 Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105)
2 A2M Alpha-2-macroglobulin
3688 ITGB1 Integrin, beta 1 (ﬁbronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12)
56944 OLFML3 Olfactomedin-like 3
1281 COL3A1 Collagen, type III, alpha 1 (Ehlers-Danlos syndrome type IV, autosomal dominant)
2274 FHL2 Four-and-a-half LIM domains 2
3688 ITGB1 Integrin, beta 1 (ﬁbronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12)Enzyme Research 9
Table 2: Continued.
Gene ID Gene symbol Full name
118427 OLFM3 Olfactomedin 3
22900 CARD8 Caspase recruitment domain family, member 8
3488 IGFBP5 Insulin-like growth factor binding protein 5
7132 TNFRSF1A Tumor necrosis factor receptor superfamily, member 1A
226 ALDOA Aldolase A, fructose-bisphosphate
3675 ITGA3 Integrin, alpha 3 (antigen CD49C, alpha 3 subunit of VLA-3 receptor)
51455 REV1 REV1 homolog (S. cerevisiae)
6421 SFPQ Splicing factor proline/glutamine-rich (polypyrimidine tract binding protein associated)
302 ANXA2 Annexin A2
4633 MYL2 Myosin, light chain 2, regulatory, cardiac, slow
8880 FUBP1 Far upstream element (FUSE) binding protein 1
2274 FHL2 Four-and-a-half LIM domains 2
3688 ITGB1 Integrin, beta 1 (ﬁbronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12)
27332 ZNF638 Zinc ﬁnger protein 638
3673 ITGA2 Integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor)
203 AK1 Adenylate kinase 1
4627 MYH9 Myosin, heavy chain 9, non-muscle
5213 PFKM Phosphofructokinase, muscle
140462 ASB9 Ankyrin repeat and SOCS box-containing 9
7076 TIMP1 TIMP metallopeptidase inhibitor 1
5176 SERPINF1 Serpin peptidase inhibitor, clade F (alpha-2 antiplasmin, pigment epithelium derived factor),
member 1
3694 ITGB6 Integrin, beta 6
59 ACTA2 Actin, alpha 2, smooth muscle, aorta
4176 MCM7 Minichromosome maintenance complex component 7
10487 CAP1 CAP, adenylate cyclase-associated protein 1 (yeast)
7046 TGFBR1 Transforming growth factor, beta receptor I (activin A receptor type II-like kinase, 53kDa)
3543 IGLL1 Immunoglobulin lambda-like polypeptide 1
5313 PKLR Pyruvate kinase, liver and RBC
51455 REV1 REV1 homolog (S. cerevisiae)
10296 MAEA Macrophage erythroblast attacher
3911 LAMA5 Laminin, alpha 5
2597 GAPDH Glyceraldehyde-3-phosphate dehydrogenase
975 CD81 CD81 molecule
92086 GGTLC1 Gamma-glutamyltransferase light chain 1
1915 EEF1A1 Eukaryotic translation elongation factor 1 alpha 1
5664 PSEN2 Presenilin 2 (Alzheimer disease 4)
1278 COL1A2 Collagen, type I, alpha 2
The interaction between CK and MYOC has not been
elucidated. However, MYOC has a cytoskeletal function, and
this implies that it may interact with CK somehow. MYOC
is expressed in many ocular tissues including the trabecular
meshwork [49], which is a specialized eye tissue that is essen-
tial in regulating intraocular pressure. MYOC mutations
have been identiﬁed as the cause of hereditary juvenile-onset
open-angle glaucoma [50].
ResearcherscouldapplycomputationalpredictionbyPPI
mapping to help determine target proteins. Since the next
step in the functional study of interesting proteins/genes is
a time- and cost-consuming process, the number of target
proteinsislimited;hence,fortherightchoice,computational
prediction on the basis of database information could
be critical at this step. Functional studies can be further
conducted using a mouse model and a large number of
clinical samples. Final conﬁrmation and CK mechanisms
could then be more clearly evaluated for developing drugs
to eﬀectively treat CK-related diseases.
Thefunctionsofmostofthecandidateproteinspredicted
in this study have not been well reported in skin diseases
or in the pathogenesis of other diseases. We provide new10 Enzyme Research
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Figure 5: Overlapping map between CKB and CKM PPI maps. Data were input by using the results from Figures 1 to 4.
information regarding these candidate proteins’ interaction
with CK, as well as the involvement of several hub proteins
such as NFKB1, FHL2, ASB9, and MYOC. Although we do
not suggest a direct role of any candidate protein in skin
diseases, we provide candidate proteins to be targeted in
further studies of CK-associated diagnostic markers and/or
treatment of corresponding skin conditions. Furthermore,
we also provide some insights into understanding the re-
sponses of CK in skin.
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CK-MM: Muscle type homodimer
CK-BB: Brain type homodimer.
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